Logo image of BTX

BlackRock Technology and Private Equity Term Trust (BTX) Stock Price, Quote, News and Overview

NYSE:BTX - New York Stock Exchange, Inc. - US1140821000 - Common Stock - Currency: USD

7.66  -0.2 (-2.54%)

After market: 7.64 -0.02 (-0.26%)

BTX Quote, Performance and Key Statistics

BlackRock Technology and Private Equity Term Trust

NYSE:BTX (2/21/2025, 8:04:35 PM)

After market: 7.64 -0.02 (-0.26%)

7.66

-0.2 (-2.54%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High10.1
52 Week Low0.17
Market Cap450.60M
Shares58.83M
Float32.20M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)11-17 2022-11-17/bmo
IPO08-29 1991-08-29


BTX short term performance overview.The bars show the price performance of BTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

BTX long term performance overview.The bars show the price performance of BTX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of BTX is 7.66 USD. In the past month the price decreased by -34.41%. In the past year, price decreased by -97.76%.

BlackRock Technology and Private Equity Term Trust / BTX Daily stock chart

BTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About BTX

Company Profile

BTX logo image Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. The company is headquartered in Brooklyn, New York and currently employs 10 full-time employees. The firm is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The firm also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.

Company Info

BlackRock Technology and Private Equity Term Trust

140 58Th Street, Building A, Suite 2100

Brooklyn NEW YORK 92009 US

CEO: Allen Wolff

Employees: 10

Company Website: https://www.buzztime.com/

Phone: 12125821199.0

BlackRock Technology and Private Equity Term Trust / BTX FAQ

What is the stock price of BlackRock Technology and Private Equity Term Trust today?

The current stock price of BTX is 7.66 USD. The price decreased by -2.54% in the last trading session.


What is the ticker symbol for BlackRock Technology and Private Equity Term Trust stock?

The exchange symbol of BlackRock Technology and Private Equity Term Trust is BTX and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is BTX stock listed?

BTX stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for BlackRock Technology and Private Equity Term Trust stock?

5 analysts have analysed BTX and the average price target is 3.06 USD. This implies a price decrease of -60.05% is expected in the next year compared to the current price of 7.66. Check the BlackRock Technology and Private Equity Term Trust stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BlackRock Technology and Private Equity Term Trust worth?

BlackRock Technology and Private Equity Term Trust (BTX) has a market capitalization of 450.60M USD. This makes BTX a Small Cap stock.


How many employees does BlackRock Technology and Private Equity Term Trust have?

BlackRock Technology and Private Equity Term Trust (BTX) currently has 10 employees.


What are the support and resistance levels for BlackRock Technology and Private Equity Term Trust (BTX) stock?

BlackRock Technology and Private Equity Term Trust (BTX) has a resistance level at 0.22. Check the full technical report for a detailed analysis of BTX support and resistance levels.


Should I buy BlackRock Technology and Private Equity Term Trust (BTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BlackRock Technology and Private Equity Term Trust (BTX) stock pay dividends?

BTX does not pay a dividend.


When does BlackRock Technology and Private Equity Term Trust (BTX) report earnings?

BlackRock Technology and Private Equity Term Trust (BTX) will report earnings on 2022-11-17, before the market open.


What is the Price/Earnings (PE) ratio of BlackRock Technology and Private Equity Term Trust (BTX)?

BlackRock Technology and Private Equity Term Trust (BTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.5).


BTX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BTX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to BTX. Both the profitability and financial health of BTX have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BTX Financial Highlights

Over the last trailing twelve months BTX reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS decreased by -23.31% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -399.71%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%75%
Sales Q2Q%N/A
EPS 1Y (TTM)-23.31%
Revenue 1Y (TTM)-100%

BTX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to BTX. The Buy consensus is the average rating of analysts ratings from 5 analysts.


Ownership
Inst Owners2.06%
Ins Owners8.14%
Short Float %N/A
Short RatioN/A
Analysts
Analysts80
Price Target3.06 (-60.05%)
EPS Next Y81.07%
Revenue Next YearN/A